Germany Demand for plasma-derived medicines continues to rise, bringing renewed attention to manufacturing capacity, supply resilience and the need for stronger plasma ecosystems. As Biotest enters its next phase of growth, CEO Jörg Schüttrumpf reflects on the company’s strategic evolution, the opportunities created by its partnership with Grifols, and the role…
Europe Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As Europe rethinks the balance between affordability, resilience and innovation, Michal Nitka, SVP, Head Generics Europe & Global Head OTC at…
Europe Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this squeeze but thriving in it – through diversification, geographic focus, R&D intensity, or sheer scientific specialisation. Here’s how four of…
Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
Ireland The first thing I’d say to innovators is to ask the patients. Patient groups are ready to support innovation, make sure we’re measuring what matters, and delivering what’s meaningful Avril Daly brings a rare dual perspective to Europe’s rare disease and ophthalmology landscape: as CEO of Retina International, she represents…
Europe The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for AbbVie, BeOne Medicines, CSL, Merz Therapeutics, and Novartis would love to see this realised and agree that Europe’s scientific fundamentals…
Europe As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over the past five years through increased investment in R&D, manufacturing, and international expansion, the company is building on the scientific…
Germany We have set out a clear strategy, but strategy only provides direction; ultimately, trust is built through execution Europe pioneered the biosimilars industry and remains its most advanced market, yet sustaining that leadership is becoming increasingly challenging as pricing pressures, manufacturing economics and global competition reshape the sector. As Formycon…
Europe The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet its ability to translate scientific excellence into timely and equitable patient access is becoming the defining challenge for the region’s…
Greece The future of Europe’s pharmaceutical industry will be shaped as much by manufacturing and industrial policy as by scientific innovation. Theodore Tryfon outlines how ELPEN is investing to strengthen healthcare resilience, expand internationally and support Greece’s emergence as a strategic pharmaceutical manufacturing hub, while reflecting on the policy choices that…
Europe Europe’s place in the global biotechnology race is entering a decisive phase. Scientific excellence and industrial depth remain powerful advantages, yet intensifying competition from the United States and China is exposing the need for faster execution, stronger capital markets, and a more coherent single market. Claire Skentelbery outlines why biotechnology…
Germany Germany and Europe have every reason to remain optimistic, provided we build on the strengths we already have As Europe seeks to strengthen its pharmaceutical resilience and Germany redefines its healthcare and industrial priorities, the decisions taken today will shape the sector’s competitiveness for decades to come. Dr Kai Joachimsen,…
See our Cookie Privacy Policy Here
